Johnson & Johnson’s subsidiary, Conor Medsystems, had attempted to revoke Angiotech’s New Zealand patent 523799, which pertains to compositions comprising a polymer and paclitaxel, as well as paclitaxel-eluting stents.
William Hunter, president and CEO of Angiotech, said: “Consistent with virtually all international rulings to date, this decision further corroborates the strength of company intellectual property and ability to defend global patent portfolio.”